Peter Voorhees, MD, discusses the latest data for the use of pomalidomide-containing regimens for the treatment of patients with relapsed/refractory multiple myeloma. He highlights data from 2 randomized clinical trials that demonstrated an improvement in responses with pomalidomide-based triplets.
Peter Voorhees, MD, a myeloma specialist at Levine Cancer Institute, discusses the latest data for the use of pomalidomide (Pomalyst)-containing regimens for the treatment of patients with relapsed/refractory multiple myeloma. He highlights data from 2 randomized clinical trials that demonstrated an improvement in responses with pomalidomide-based triplets.
There have been several randomized clinical trials that have demonstrated superiority of pomalidomide-based combinations, Voorhees says. The phase II ELOQUENT-3 trial, in particular, looked at the combination of pomalidomide plus dexamethasone with or without elotuzumab (Empliciti). Results showed that patients had a higher likelihood of responding to the 3-drug regimen as compared with the 2-drug combination, and the depth of response also improved with the addition of elotuzumab. This translated to a significant improvement in median progression-free survival (PFS).
These phase II data led to theFDA approval of elotuzumab in combination with pomalidomide and low-dose dexamethasonefor the treatment of patients with relapsed/refractory multiple myeloma who have received at least 2 prior lines of therapies.
In the randomized phase III ICARIA-MM trial, presented at the 2019 ASCO Annual Meeting,the triplet regimen of pomalidomide, dexamethasone, and isatuximab also led to similar findings
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More